Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose

Hislop, JenniferMowatt, GrahamSharma, PawanaFraser, CynthiaElders, AndrewJenkinson, DavidVale, LukePetty, Russell2012-06-082012-06-082012-06Hislop, J, Mowatt, G, Sharma, P, Fraser, C, Elders, A, Jenkinson, D, Vale, L & Petty, R 2012, 'Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose', Journal of Gastrointestinal Cancer, vol. 43, no. 2, pp. 168-176. https://doi.org/10.1007/s12029-011-9325-61941-6628http://hdl.handle.net/2164/2482PMID: 21971958 [PubMed - indexed for MEDLINE] PMCID: PMC3348468 Free PMC Article This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited9218536engSDG 3 - Good Health and Well-beingGISTgastrointestinal stromal tumoursunresectablemetastaticcancerimatinibsunitinibantineoplastic agentsbenzamidesclinical trials as topicdisease progressiondose-response relationshipgastrointestinal stromal tumorshumansindolespiperazinespyrimidinespyrrolestreatmemnt outcomeRC0254 Neoplasms. Tumors. Oncology (including Cancer)RC0254Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib DoseJournal article10.1007/s12029-011-9325-6432